Insulin glargine and cancer risk: An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

Krystal L. Edwards, Daniel M. Riche, Jeffrey S. Stroup, Jennifer D. Goldman-Levine, Rosalyn S. Padiyara, L. Brian Cross, Michael P. Kane

Research output: Contribution to journalComment/debate

7 Scopus citations

Abstract

Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.

Original languageEnglish
Pages (from-to)955-965
Number of pages11
JournalPharmacotherapy
Volume30
Issue number9
DOIs
StatePublished - Sep 2010

Keywords

  • Cancer
  • Diabetes
  • Insulin
  • Insulin glargine
  • Oncology

Fingerprint Dive into the research topics of 'Insulin glargine and cancer risk: An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy'. Together they form a unique fingerprint.

  • Cite this